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CC BY-NC-ND license (http://creativeAbstract Current estimates indicate that the hepatitis C (HCV) is the leading cause ofmortality
around the world, with infection rates steadily increasing in Egypt. The dual therapy for this si-
lent epidemic with pegylated-interferon-a2b/ribavirin has markedly improved the success rates
in genotype-4 patients. It was reported that apoptosis plays a vital mechanistic role in limiting
viral replication. P53, a key regulator of apoptosis, induces CD95 gene expression and subse-
quently initiates apoptotic cascade to be activated. The current study examined the impact of
P53 rs1042522 and CD95 rs1800682 polymorphisms on the treatment response. Three groups of
240 volunteers were enrolled in this study; 86 in sustained virological responders group, 74 in
non-responders group, and 80 in control group. All patients had HCV genotype-4a andwere inter-
feron treatment naı¨ve. Quantizations of HCV-RNA by qRT-PCR and histological scores were per-
formed for all patients. In addition, genotyping of HCV-RNA, P53 rs1042522 Arg/Pro and CD95
rs1800682 A/G polymorphisms were investigated in all subjects. It was resulted that P53 Pro/Pro
homozygous genotype has high significant increase, while CD95 A/A homozygous genotype has
high significant decrease when comparing non-responders with responders. Finally, it was
concluded that Pro variant of P53 rs1042522 may be used as a genetic predictor for non-respon-
siveness, while A/A variant of CD95 rs1800682 may be used as a sensitive biomarker for respon-
siveness to antiviral therapy of HCV genotype-4a infection. In addition, low prolactin, high totalyahoo.com (A.A. Abd-Rabou).
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response when associated with these genetic polymorphisms.
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Globally, the hepatitis C virus (HCV) is the main cause of
mortality and it was identified 25 years ago.1 Since then,
HCV infection has spread and its distribution varies broadly
among various geographic areas. Africa and Asia have the
highest reported rates of infections (more than 2.9%), while
industrialized regions like America and Europe have lower
rates of infections (less than 1%).2 Recent epidemiological
data indicate that infection steadily increased from 2.3% to
2.8% between 1990 and 2005.3
Pre-clinical and clinical outputs in these industrial areas
promise high response rates with some adverse effects
following treatment with dual or triple direct-acting anti-
viral agents (DAA) therapy. However, such DAAs are
designed with genotype 1 as the principle target and often
have limited pan-genotypic efficacy or have yet to be
approved for use against other genotypes. In 2015, it was
reported that successful treatment for HCV is made diffi-
cult by the presence of various hosts, viruses, and
treatment-related factors. The addition of telaprevir and
boceprevir to the arsenal improved success rates in geno-
type 1 infected patients from roughly 40% in treatment-
naı¨ve patients with interferon-based dual therapy to 60.8%
and 54.2%, respectively, but rapid development of resis-
tance mechanisms, increases in adverse effects, and a low
spectrum activity proved to be barriers to efficacious
treatment.4
In late 2013, two new agents were approved e sofos-
buvir and simeprevir e which have higher barriers to
resistance and drastically improved success rates; however
cost concerns could limit their utilization, especially in
developing countries like Egypt. Sofosbuvir costs approxi-
mately $1000 per pill, because the wholesaler acquisition
cost of a four week supply is $28,000. Depending on geno-
type, sofosbuvir costs $84,000 and $168,000 for 12 and 24
week-based treatment, without taking into considerations
of costs of ribavirin and peginterferon. Not only does this
add an additional burden to the health care system, but
could also prevent patients from getting access.4,5
There are 11 genetically distinct genotypes and more
than 50 subtypes of the virus that have been identified.6
Genotype 1 and 4 are often considered more difficult to
treat than genotype 2 and 3,7 leaving patients with
genotype-4 with fewer treatment options, even though
genotype-4 is common in Egypt and throughout the Middle
East and Africa.8 Consequently, there is a continuous need
for promising biomarkers for the interferon-based therapy.
IFN-l3, coded by the interleukin 28B (IL28B) gene, is a
cytokine9 involved in the antiviral immune response and
inhibits HCV replication in vitro.10 Recently, the impact of
the IL28B gene SNPs on HCV treatment was discovered andit has been studied in several ethnicities and various viral
genotypes.11e13 Major findings include the association of
the minor alleles (rs12979860, rs8099917, and rs12980275)
with non-responsiveness to interferon-based antiviral
therapy. IL28B rs12980275 polymorphism was not found in
HCV genotype 2 and 3 infected patients.14,15 Although SNPs
in the IL28B locus are probably the most well-known pre-
dictors of outcome of interferon therapy, the effect has
been less widely examined in genotype-4a and there are
unfavorable effects varied between ethnicities (European-
Americans: OR 7.3, African-Americans: OR 6.1, Hispanics:
OR 5.6), some interethnic variability in treatment response
may be explained by this variant.11 Consequently, there is
an unmet need for novel biomarkers for response to
interferon-based therapy.
Teodoro and Branton have suggested that apoptosis, a
biological phenomenon that plays a crucial role in immune
regulation and tissue homeostasis, is an important ma-
chinery in limiting viral replication. In addition, apoptosis
induction upon HCV infection may contribute to viral
clearance, while its inhibition may result in HCV persis-
tence and oncogenesis.16 BCL2 gene, a key regulator of
apoptosis, has a single nucleotide polymorphism at codon
43 (127G/A) and it is recently reported that this poly-
morphic point can be used as a sensitive biological marker
for early prediction of 56.1% response rate to interferon-
based therapy.17
Over 25 years ago, a new P53 single nucleotide poly-
morphism located at codon 72 (rs1042522) and associated
with arginine to proline (Arg/Pro) substitution has been
identified.18 Thereafter, numerous observations examined
the role of P53 rs1042522 Arg/Pro polymorphism on hepa-
tocellular carcinoma (HCC) and HCV-associated HCC in-
cidences. Scientists suggested that there was a frequent
loss of P53 rs1042522 Pro allele in HCV-positive carriers.19
On the contrary, others found that there was no associa-
tion between P53 rs1042522 genotypes and disease severity
or hepatocarcinogenesis.20
In HCV infection, CD95 expression was found to be up-
regulated within hepatocytes in accordance with the
severity of liver inflammation.21 These CD95-expressing
hepatocytes become susceptible to the apoptotic death
signal and play a crucial role in liver cell injury caused by
HCV infection.22 CD95-670A/G (rs1800682) polymorphism
was associated potentially with fibrosis and cirrhosis in
patients infected with HCV.23 In addition, authors have
suggested that there was a higher frequency of CD95
rs1800682 A/A genotype in spontaneously recovered pa-
tients from HCV infection compared to patients with
persistent HCV infection.24 On the contrary, other scientists
have demonstrated that there was no significant correlation
between CD95 rs1800682 polymorphism and fibrotic stages,
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topathological variations in HCV infections.25
Some hormones play a significant role in immune cells
regulation such as B-cells, T-cells, and natural killer cells.
This advantage supports their vital roles in chronic liver
disease resistance and attack from early stages of
infections.26e29 It was suggested that HCV infected patients
have high prolactin concentrations,30,31 regardless of
gender.32 Besides, prolactin concentrations decreased
significantly after antiviral therapy in responders compared
to non-responders33; regardless of gender.32 Meanwhile,
there were high significant decreases of post-treatment
total testosterone concentrations when comparing males
of non-responders with responders.32 In addition, it was
investigated that patients infected with HCV showed a
significant decrease in human growth hormone levels
compared to healthy subjects. Whereas, growth hormone
concentrations increased after antiviral therapy in re-
sponders compared to non-responders.34,35
Overall, these observations promoted us to study the
impact of the P53 rs1042522 and CD95 rs1800682 poly-
morphisms on the response to pegylated-interferon-based
antiviral therapy among HCV genotype-4a infected pa-
tients. In addition, the previous observations of hormonal
profile alterations during antiviral therapy guided us to
examine the association between these hormonal alter-
ations and the genetic polymorphisms as well as their
impact on the treatment response.
Materials and methods
Study patients
Two hundred and forty volunteers were enrolled in this
prospective study and divided into 3 groups; 86 in sustained
virological responders group, 74 in non-responders group,
and 80 in healthy controls group. The 160 patients who were
infected with HCV visited outpatient clinics of the Tropical
Medicine and Hepatology Department, El-Kasr El-Aini Hos-
pital, Cairo University, Egypt; where they were diagnosed
with chronic HCV infection. All volunteers were enrolled in
the current study after signing a consent form. The patients
were treated with subcutaneous injections of pegylated-
interferon-a 2b (Reiferon Retard, Minapharm, Cairo, Egypt)
(100 mg/week) combined with oral administration of riba-
virin (Minapharm, Cairo, Egypt) (1000e1200 mg/day, body
weight based) for 24 weeks. Patients were grouped ac-
cording to treatment response. At week 24, 86 patients were
tested negative with undetectable HCV-RNA and classified as
responders, then continued treatment until week 48 to
detect sustained virological response when the viral RNA
remains undetected after six months of treatment cessa-
tion. Those who tested positive for HCV-RNA (n Z 74)
stopped treatment at week 24 and were classified as non-
responders. The study protocol and informed consent were
approved by the Ethics Committee of Cairo University.
Patients inclusion and exclusion criteria
Patients participated in the study were fulfilled the inclusion
criteria included: elevated hepatic enzymes; ALT and AST(>37 IU/L); within 6 months prior to entry the study, hemo-
globin (>11 g/dL), total leucocytes count (>3000/mm3),
neutrophils (>1500/mm3), platelets (>100,000/mm3),
prothrombin timewithin normal range (9.8e13.8 s, presence
of antinuclear antibodies (ANA titre <1/160), positive HCV
antibodies, detectable HCV-RNA, HCV genotype-4a, liver
biopsy showing histological evidence of chronic hepatitis and
they were never previously treated with interferon. On the
other hand, patients presented with HCC, liver diseases
other than hepatitis C such as hepatitis B surface antigen
(HBsAg) seropositivity or autoimmune hepatitis or co-
contamination with the human immunodeficiency virus
(HIV) and active schistosomiasis were excluded from this
study.
Biochemical and hormonal tests
Biochemical tests including liver enzymes (ALT, and AST),
total bilirubin, direct bilirubin, albumin, and alpha feto-
protein (AFP) were performed on patients infected with
HCV genotype-4a and treated with PEG-IFN-a/RBV antiviral
therapy on Integra-400 (Roche, Mannheim, Germany).
Human prolactin, total testosterone, and growth hormone
were quantified in all patients infected with HCV using the
enzyme-linked immunosorbent assay (ELISA). Enzyme
immunoassay (EIA) was used for the quantitative determi-
nation of prolactin and total testosterone concentrations
was measured using ELISA kits purchased from Immunospec
Corporation (California, USA). Meanwhile, human growth
hormone levels were measured using ELISA kits supplied by
DRG International (Mountainside, USA). All these measure-
ments were examined before, during and after the combi-
nation therapy.
Histological investigations
Patients infected with chronic HCV were subjected to
abdominal ultrasound and liver biopsy was taken from each
patient before the onset of therapy to estimate the grade
of activity and fibrosis according to metavir scoring sys-
tem.36 All biopsies were classified into 5 stages of fibrosis
(F0: no fibrosis; F1: enlargement of portal tract without
septa formation; F2: enlargement of portal tract with rare
septa formation; F3: numerous septa without cirrhosis; F4:
established cirrhosis) and 4 grades (inflammations) of his-
tological activity (A0: none; A1: mild; A2: moderate; A3:
severe) based on the intensity of necroinflammatory
lesions.
HCV detection
The presence or absence of HCV antibodies was investi-
gated by the third generation ELISA (DiaSorin, Torino,
Italy). HCV-RNA in serum was measured before treatment
and routinely at week 24 and 48 after treatment and
graded into low (200,000e1,000,000 copies/mL), moder-
ate (1,000,000e5,000,000 copies/mL), and high
(5,000,000e25,000,000 copies/mL) viral levels.
RNA was extracted from sera using a Qiagen viral RNA kit
(Qiagen, Hilden, Germany), then real time reverse tran-
scription polymerase chain reaction (qRT-PCR) was
200 A.A. Abd-Rabou et al.performed using a LightCycler system (Roche, Mannheim,
Germany). Amplification primers for HCV were 50 primer
K78F (CAAGCACCC TATCAGGCAGT) and 30 primer K80R
(AGCGTCTAGCCATGGCGT). Hybridization probes (FL) 50-
GCAGCCTCCAGGACCCCCC-30 and (LC) 50-CCCGGGA-
GAGCCATAGTGGTCTG-30 were used to detect the product.
Reaction mixtures included 7.5 ml of Lightcycler RNA Master
HybProbe, 3.25 mM Mn(OAc)2, 0.5 mM concentration of each
primer, 0.4 mM of hybridization probe mix and 1 ml of the
RNA template in a total volume of 20 ml. HCV-RNA was first
reverse-transcribed at 61 C for 20 min. Following dena-
turation for 30 s at 95 C, the LightCycler amplification was
performed for 45 cycles, each cycle consisting of 5 s at
95 C, annealing at 62 C for 15 s and extension at 72 C for
10 s. Fluorescence was monitored at 530/640 nm.
HCV-RNA genotyping
RNA was isolated from sera for HCV genotyping using a
Qiagen viral RNA kit (Qiagen, Hilden, Germany). HCV-RNA
genotyping was performed using Ohno method which de-
pends on nested PCR amplification of the virus core gene
using genotype specific primers mentioned previously.37
P53 rs1042522 and CD95 rs1800682 genotyping
The single nucleotide polymorphisms of P53 rs1042522 and
CD95 rs1800682 were studied to find whether these poly-
morphisms have an impact on HCV response to interferon-
based therapy. The DNA was extracted from whole blood of
all individuals using QIAamp DNA blood Mini kit (Qiagen,
Hilden, Germany). PCR was performed using the thermal
cycler (Biometra, Go¨ttingen, Germany) for amplifying P53
and CD95 genes. PCR reagents were supplied by (Promega,
Southampton, UK). Primer sequences were as follow: the
forward primer (F): 50- TTG CCG TCC CAA GCA ATG GAT GA-
30 and the reverse primer (R): 50-TCT GGG AAG GGA CAG
AAG ATG AC-30 for P53 gene and the forward primer (F): 50-
CCT AAG AGC TAT CTA CCG TTC-30 and the reversed primer
(R): 50-GGC TGT CCA TGT TGT GGC TGC-30 for CD95 gene.
The PCR products of P53 and CD95 gene amplification yield
199 bp and 233 amplicons respectively. The PCR conditions
of P53 and CD95 were as follow: denaturation at 95 C for
30 s, annealing at 60 C and 58 C respectively for 30 s, and
extension at 72 C for 30 s. These amplicons were enrolled
in restriction fragment length polymorphism (RFLP) tech-
nique after purification.Table 1 Description of PCR and RFLP products of P53 and CD95
Gene SNPs PCR amplicon RF
P53 þ72 G/C (Arg72Pro) 199 bp Bs
CD95 670 A/G 233 bp Mv
SNPs: single nucleotide polymorphisms.
RFLP: restriction fragment length polymorphism.
R.E.: restriction enzyme.The purified PCR products of P53 and CD95 genes were
incubated at 37 C overnight with Bsh1236I and BstNI re-
striction enzymes respectively to identify three different
genotypes of each gene as described in numerous previous
studies [19, 20, 23, 25, 38] and illustrated in Table 1. Re-
striction enzymes were purchased from (Fermentas,
Ontario, Canada). Amplified DNA or digested PCR Products
was loaded and electrophoresed on a 3% agarose gel pre-
pared in 1  TBE buffer using a gated mini-gel tank (BioRad,
California, USA) and containing ethidium bromide (0.5 mg/
ml) for 40 min at 100 V. DNA ladder (Fermentas, Ontario,
Canada) was routinely used as a molecular weight standard
as a reference in the agarose gel. The gel was visualized on
a UV gel documentation computerized system. Images were
manipulated by BioDocAnalyze software program (Bio-
metra, Go¨ttingen, Germany).
Biostatistics
The data have been expressed as mean  standard error
(S.E.) and the range was stated between parentheses.
Comparison of variables between the study groups has been
done using analysis of variance (ANOVA) test. Data were
statistically described using statistical computer program:
SPSS (Statistical Package for the Social Science, USA,
version 17). For comparing categorical data, Chi-square
(c2) test was performed. A Chi-square (c2) less than 3.84
was considered as a non-statistically significant value and
(c2) more than 3.84 was considered as a statistically sig-
nificant value. A receiver operating characteristic (ROC)
analysis was used to determine the area under ROC curve
(AUC), sensitivity, and specificity for the studied prognostic
markers. To rank the importance of predictor variables,
logistic regressions of some promising variables were
performed.
Results
Demographic and clinical data
Data for all HCV genotype-4a infected patients and treated
with pegylated-interferon-a plus ribavirin (PEG-IFN-a/RBV)
as well as control subjects were collected. There was no
significant difference of age, gender, and body mass index
(BMI) when comparing sustained virological responders
(SVR) with either non-responders (NR) or controls (p > 0.05)genes.
LP (R.E.) Genotypes Product sizes (bp)
tUI (Bsh1236I) þ72 G/G 113 þ 86
þ72 C/C 199
þ72 G/C 199 þ 113 þ 86
aI (BstNI) 670 A/A 233 þ 99
670 G/G 189 þ 99 þ 44
670 A/G 233 þ 189 þ 99 þ 44
Genetic variations in HCV-4a response 201as shown in Table 2. In addition, the hepatic function tests,
including AST, ALT, total bilirubin, direct bilirubin, albumin,
and AFP of 86 SVR against 74 NR patients (pre- and post-
treatment with PEG-IFN-a/RBV) were analyzed; where
there were high significant increases (p < 0.01) of post-
treatment ALT, AST, direct bilirubin, and albumin as well
as a significant increase (p < 0.05) of post-treatment total
bilirubin when comparing responders with non-responders.
On the contrary, there was no significant difference
(p > 0.05) of pre-treatment AST, ALT, total bilirubin, direct
bilirubin, albumin, and AFP as well as post-treatment AFP
when comparing SVR with NR patients. Finally, there were
high significant differences (p < 0.01) of pre-treatment
ALT, AST, total bilirubin, direct bilirubin, and AFP levels
when comparing either SVR or NR patients with controls.
Virological and histological data
The metavir scoring system including hepatic activity scores
(A0/1 and A2/3) and fibrotic stages (F0/1, F2, and F3/4) as
well as the low, moderate, and high viral loads were
collected from 86 SVR and 74 NR patients (pre- and post-
treatment with PEG-IFN-a/RBV); where there were high
frequency and significant differences of the low, moderate,
and high viral loads when comparing post-treated SVR with
NR patients (c2Z 48.31, 66.69, 6.38; respectively). On the
contrary, there was no significant difference (p > 0.05) of
the low, moderate, and high viral loads when comparing
pre-treated SVR with NR patients (c2 Z 3.183, 0.247,
3.678; respectively) as illustrated in Table 3.Table 2 Demographic and clinical data of all subjects.
Characteristics (Mean  S.E.) Controls (n Z 80)
Age, (years)
Range, (minemax)
39.85  6.61
(19.00e53.00)
Gender
Females, n (%) 36 (45%)
Males, n (%) 44 (55%)
BMI, (kg/m2) 24.30  6.26
ALT, (IU/L), A 30.40  0.94
ALT, (IU/L), B e
AST, (IU/L), A 32.12  1.19
AST, (IU/L), B e
Total Bilirubin, (mg/dL), A 0.78  0.03
Total Bilirubin, (mg/dL), B e
Direct Bilirubin, (mg/dL), A 0.15  0.01
Direct Bilirubin, (mg/dL), B e
Albumin, (g/dL), A 4.34  0.13
Albumin, (g/dL), B e
AFP, (U/L), A 4.11  0.19
AFP, (U/L), B e
S.E.: standard error.
n: size of samples.
A: before treatment.
B: after treatment.
a/a*: a significant/a high significant correlation (c2 > 3.84) when com
b/b*: a significant/a high significant correlation (c2 > 3.84) when com
c/c*: a significant/a high significant correlation (c2 > 3.84) when com
d: a non-significant correlation (c2 < 3.84) either when comparing noRegarding the metavir scoring system, there were high
frequency and significant differences of pre-treatment
hepatic activity scores (A0/1 and A2/3) and liver fibrotic
stages (F0/1, F2, and F3/4) when comparing SVR with NR
patients (c2 Z 4.34, 4.34, 28.6, 6.04, 11.12; respec-
tively). On the other hand, there were high frequency and
significant differences of post-treatment hepatic activity
scores (A0/1 and A2/3) and liver fibrotic scores (F0/1 and
F3/4) when comparing SVR with NR patients (c2 Z 20.20,
20.20, 11.17, 33.09; respectively). On the contrary, there
was no significant difference (p > 0.05) of pre-and post-
treatment hepatic fibrotic score (F2) when comparing SVR
with NR patients (c2 Z 0.01, 3.33; respectively) as shown
in Table 3.
Identification of P53 rs1042522 and CD95
rs1800682 genetic variants
In all patients infected with HCV and healthy individuals,
Bsh1236I restriction enzyme was used to distinguish be-
tween P53 rs1042522 Arg/Arg, Pro/Pro, and Arg/Pro.
Bsh1236I digestion of the PCR amplicon (199 bp) was
performed to identify the three different genotypes of
P53: the homozygous Arg72Arg (þ72 G/G) genotype at
(113 bpþ86 bp), the homozygous Pro72Pro (þ72 C/C) ge-
notype at (199 bp), and the heterozygous Arg72Pro
(þ72 G/C) genotype at (199 bpþ113 bpþ86 bp) as illus-
trated in Fig. 1.
Additionally, the BstNI digestion of the PCR amplicon
(233 bp) was used to discriminate CD95 rs1800682 A/A,SVR (n Z 86/160, 53.7%) NR (n Z 74/160, 46.3%)
41.17  6.91d
(20.00e53.00)
39.08  6.94d
(20.00e54.00)
44 (51.2%)d 38 (51.4%)d
42 (48.8%)d 36 (48.6%)d
25.20  5.24d 26.04  6.53d
60.00  2.54a* 54.00  3.47b*
33.73  2.83 41.88  4.17c*
62.13  2.61a* 60.35  3.85b*,d
34.26  1.19 65.11  4.39c*
1.05  0.08a* 1.15  0.04b*,d
0.78  0.01 1.22  0.1c
0.24  0.02a* 0.26  0.03b*,d
0.14  0.01 0.31  0.04c*
3.86  0.04a 3.77  0.1b*,d
3.28  0.02 3.90  0.07c*
5.77  0.37a 6.02  0.41b*,b
4.64  0.29 5.34  0.46b
paring responders with controls.
paring non-responders with controls.
paring non-responders with responders.
n-responders or responders with controls.
Table 3 Baseline virological and histological features of HCV sustained virological responders (SVR) against non-responders
(NR).
Virological and histological features SVR (n Z 86) NR (n Z 74) c2 P
Size (n) Frequency (%) Size (n) Frequency (%)
HCV-RNA Level, before therapy
Low viral load 43 50.0 27 36.5 3.1 NS
Moderate viral load 39 45.3 37 50.0 0.2 NS
High viral load 4 4.7 10 13.5 3.6 NS
HCV-RNA Level, after therapy
Low viral load 0 0 30 40.5 48.3 S*
Moderate viral load 0 0 38 51.4 66.6 S*
High viral load 0 0 6 8.1 6.3 S
Metavir Scoring System, before therapy
Activity Score
A0/1 72 83.7 52 70.3 4.3 S
A2/3 14 16.3 22 29.7 4.3 S
Fibrosis Score
F0/1 54 62.8 18 24.3 28.6 S*
F2 20 23.3 30 40.5 6.04 S
F3/4 12 13.9 26 35.2 11.1 S
Metavir Scoring System, after therapy
Activity Score
A0/1 76 88.4 44 59.5 20.2 S*
A2/3 10 11.6 30 40.5 20.2 S*
Fibrosis Score
F0/1 56 65.1 30 40.5 11.1 S
F2 24 27.9 12 16.2 3.3 NS
F3/4 6 7 32 43.3 33.0 S*
n: size of samples.
NS: represents no significant difference.
S: represents significant difference with Chi-square value (c2 > 3.84).
S*: high significant difference with Chi-square value (c2 > 3.84).
202 A.A. Abd-Rabou et al.G/G, and A/G among HCV infected patients and
healthy controls. BstNI/RFLP analysis was performed
to identify the different three types of CD95
genotypes; the homozygous 670 A/A genotype at (233Figure 1 Detection of the P53 polymorphism by PCR-BstUI dig
homozygous Arg72Arg and the heterozygous Arg72Pro but does not
DNA Marker (100 bp), lane 1 and 2 represent the homozygous Pro72
heterozygous Arg72Pro (þ72 G/C) genotype at (199 bp þ113 bp þ 8
G) genotype at (113 bp þ86 bp).bpþ99 bp), the homozygous 670 G/G genotype at (189
bpþ99 bpþ44 bp), and the heterozygous 670 A/G ge-
notype at (233 bpþ189 bpþ99 bpþ44 bp) as illustrated in
Fig. 2.estion. BstUI restriction enzyme cuts the PCR products of the
cut the homozygous Pro72Pro PCR fragment. Lane M represents
Pro (þ72 C/C) genotype at (199 bp), lane 3 and 5 represent the
6 bp), and lane 4 represents the homozygous Arg72Arg (þ72 G/
Figure 2 Detection of the CD95 polymorphism by PCR-MvaI digestion. MvaI restriction enzyme cuts the PCR products of the
homozygous 670 G/G and the heterozygous 670 A/G but does not cut the homozygous 670 A/A PCR fragment. Lane M rep-
resents DNA Marker (100 bp), lane 1 and 3 represent the homozygous 670 G/G genotype at (189 bpþ99 bpþ44 bp), lane 2 and 5
represent the heterozygous 670 A/G genotype at (233 bpþ189 bpþ99 bpþ44 bp), and lane 4 represent the homozygous 670 A/A
genotype at (233 bpþ99 bp).
Table 4 Frequencies of P53 and CD95 polymorphic spots
at þ72 G/C and 670 A/G respectively in all subjects.
Genotypes/
Alleles/models
Controls
(n Z 80)
SVR
(n Z 86)
NR
(n Z 74)
n % n % n %
P53 General genotypes
72 G/G (Arg/Arg) 42 52.5 38 44.2c 24 32.4a
72 G/C (Arg/Pro) 33 41.3 44 51.2c 26 35.2c
72 C/C (Pro/Pro) 5 6.2 4 4.6c 24 32.4a*,b*
P53 Alleles frequency
72 G (Arg) 117 73.1 120 69.8c 76 50a
72 C (Pro) 43 26.9 52 30.2c 74 50a
P53 Dominant model
Arg/Arg 42 52.5 38 44.2c 24 32.4a
Arg/Pro þ Pro/Pro 38 47.5 48 55.8c 50 67.6a
P53 Recessive model
Arg/Arg þ Arg/Pro 75 93.7 82 95.4c 50 67.6a*,b*
Pro/Pro 5 6.3 4 4.6c 24 32.4a*,b*
CD95 Genotypes
670 A/A 29 36.3 28 32.6c 8 10.8a,b
670 A/G 34 42.5 42 48.8c 45 60.8a
670 G/G 17 21.2 16 18.6c 21 28.4c
CD95 Alleles frequency
670 A 92 57.5 98 57c 61 41.2c
670 G 68 42.5 74 43c 87 58.8c
CD95 Dominant model
A/A 29 36.3 28 32.6c 8 10.8a,b
A/G þ G/G 51 63.7 58 67.4c 66 89.2a,b
CD95 Recessive model
A/A þ A/G 63 78.7 70 81.4c 53 71.6c
c c
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polymorphisms
Table 4 shows the frequencies of P53 rs1042522 and CD95
rs1800682 genetic polymorphisms at þ72 Arg/Pro and 670
A/G respectively in patients treated with PEG-IFN/RBV and
healthy controls. Non-responders have high frequencies
and significant increases of P53 rs1042522 Pro/Pro genotype
and allele (nZ 24, 32.43% vs. nZ 4, 4.6%; nZ 74, 50% vs.
n Z 52, 30.23%, respectively), while have a low frequency
and significant decrease of P53 rs1042522 Arg/Pro genotype
(nZ 26, 35.14% vs. nZ 44, 51.2%, respectively) compared
to responders. On the other hand, responders have a high
frequency and significant increases of CD95 rs1800682 A/A
genotype and allele (n Z 28, 32.6% vs. n Z 8, 10.8%;
n Z 98, 57% vs. n Z 61, 41.2%, respectively), while there
was no significant difference of P53 rs1042522 Arg/Arg ge-
notype as well as CD95 rs1800682 A/G and G/G genotypes
when comparing NR with SVR patients.
In addition, Table 4 shows that there was no significant
difference of all P53 and CD95 genetic variants (c2> 3.84)
when comparing responders with controls, while there
were high significant differences of P53 rs1042522 Pro/Pro
genotype and recessive model (Pro/Pro vs Arg/Arg plus
Arg/Pro) as well as significant differences (c2< 3.84) of
P53 rs1042522 Arg/Arg genotype and dominant model
(Arg/Arg vs Pro/Pro plus Arg/Pro) when comparing non-
responders with controls. On the other side, non-
responders have significant differences (c2< 3.84) of
CD95 rs1800682 A/A and A/G genotypes as well as the
dominant model (A/A vs. G/G plus A/G) compared to
controls.G/G 17 21.3 16 18.6 21 28.4
n: size of samples.
a/a*: a significant/a high significant correlation when
comparing non-responders with controls.
b/b*: a significant/a high significant correlation when
comparing non-responders with responders.
c: a non-significant correlation either when comparing non-re-
sponders or responders with controls.Response rates of P53 rs1042522 and CD95
rs1800682 polymorphisms
Table 5 shows the treatment response frequencies of P53
rs1042522 Arg/Pro and CD95 rs 1800682 A/G genetic
polymorphisms in patients treated with PEG-IFN/RBV in
Table 5 Response rates of P53 and CD95 genotypes and
alleles as well as dominant and recessive models at þ72 G/C
and 670 A/G polymorphic points.
Genotypes/
Alleles/models
SVR NR c2 P
Size
(n)
Frequency
(%)
Size
(n)
Frequency
(%)
P53 General genotypes
72 G/G (Arg/Arg) 38 61.3 24 38.7 9.3 S
72 G/C (Arg/Pro) 44 62.9 26 37.1 12.3 S
72 C/C (Pro/Pro) 4 14.3 24 85.7 99.1 S*
P53 Alleles frequency
72 G (Arg) 120 61.2 76 38.8 9.1 S
72 C (Pro) 52 41.3 74 58 .7 5.3 S
P53 Dominant model
Arg/Arg 38 61.3 24 38.7 9.3 S
Arg/Pro þ
Pro/Pro
48 49 50 51 0.0 NS
P53 Recessive model
Arg/Arg þ
Arg/Pro
82 62.1 50 37.9 10.7 S
Pro/Pro 4 14.3 24 85.7 99.1 S*
CD95 Genotypes
670 A/A 28 77.8 8 22.2 59.6 S*
670 A/G 42 48.3 45 51.7 0.1 NS
670 G/G 16 43.2 21 56.8 3.1 NS
CD95 Alleles frequency
670 A 98 61.6 61 38.4 9.8 S
670 G 74 46 87 54 0.9 NS
CD95 Dominant model
A/A 28 77.8 8 22.2 59.6 S*
A/G þ G/G 58 46.8 66 53.2 0.5 NS
CD95 Recessive model
A/A þ A/G 70 56.9 53 43.1 3.2 NS
G/G 16 43.2 21 56.8 3.1 NS
n: size of samples.
c2-value; represent Chi-square calculated value.
NS: no significant difference with Chi-square value (c2 < 3.84).
S: significant difference with Chi-square value (c2 > 3.84).
S*: high significant difference with Chi-square value (c2 > 20).
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alleles, dominant, and recessive models in SVR and NR
patients as well as to detect which variant has the po-
tentiality to be used for early response prediction. It was
observed that P53 rs1042522 Pro/Pro genotype and allele
have high frequencies and significant increases when
comparing NR with SVR (n Z 24, 85.7% vs. n Z 4, 14.3%;
n Z 74, 58.7% vs. n Z 52, 41.3%, respectively). Addi-
tionally, P53 rs1042522 Arg/Arg genotype and allele, Arg/
Pro genotype, and P53 recessive model (Arg/Arg þ Arg/
Pro) have high frequencies and significant increases when
comparing SVR with NR patients (nZ 38, 61.3% vs. nZ 24,
38.7%; n Z 44, 62.9% vs. n Z 26, 37.1%; n Z 82, 62.1% vs.
n Z 50, 37.9%; n Z 120, 61.2% vs. n Z 76, 38.8%,
respectively). On the other hand, CD95 rs1800682 A/A
genotype and allele have high frequencies and significant
increases when comparing SVR with NR patients (n Z 28,
77.8% vs. n Z 8, 22.2%; n Z 98, 61.6% vs. n Z 61, 38.4%,
respectively).Association between hormonal profile and
genotypes of P53 and CD95 in term of treatment
response
The association between the hormonal profile, including
prolactin, total testosterone, and growth hormone levels,
as well as the genetic polymorphisms of P53 rs1042522 and
CD95 rs1800682 was summarized in Table 6 among SVR and
NR patients. This table showed that responders have high
significant decreases of prolactin levels in case of P53
rs1042522 C/C genotype and CD95 rs1800682 A/A genotype
(p < 0.01), high significant increases of total testosterone
concentrations in case of P53 rs1042522 C/C genotype
(p < 0.01), and significant increases of growth hormone
levels in case of P53 rs1042522 G/G genotype (p < 0.01) and
CD95 rs1800682 A/A genotype (p < 0.05) compared to non-
responders.
Logistic regression analyses
Table 7 summarizes the different logistic regressions of the
human pre- and post-treatment prolactin and testosterone
against different independent variables of hormonal and
biochemical measured parameters in HCV responders and
non-responders. Regression analysis for pre-treatment
prolactin showed a significant positive correlation with
post-treatment prolactin and a significant negative corre-
lation with post-treatment testosterone in HCV responders
and non-responders (p < 0.01). Meanwhile, pre-treatment
prolactin showed a significant positive correlation with
pre-treatment total bilirubin in responders (p < 0.005). On
the other side, post-treatment testosterone had a signifi-
cant positive correlation with pre-treatment testosterone
and vice versa in HCV responders and non-responders
(p < 0.01).
Response rates of P53 rs1042522, CD95 rs1800682
versus IL28B rs12979860 and BCL2 rs1800477
polymorphisms
The treatment response rates of IL28B rs1297986039 versus
P53 rs1042522, CD95 rs1800682, and BCL2 rs180047717
polymorphisms in HCV genotype-4 infected patients were
illustrated in Fig. 3. IL28B rs12979860 C/C, P53 rs1042522
Arg/Arg (G/G), CD95 rs1800682 A/A, and BCL2 rs1800477 A/
A genotypes have high treatment response rates compared
to the remaining genotypes of the same polymorphic
points. There was no significant difference of sustained
virological response rates when comparing IL28B
rs12979860 C/C variant with CD95 rs1800682 A/A variant
and IL28B rs12979860 C/T variant with P53 rs1042522 Arg/
Pro (G/C) variant. On the other side, there were significant
increases of sustained virological response rates when
comparing IL28B rs12979860 C/C variant with either P53
rs1042522 G/G variant or BCL2 rs1800477 G/G variant
(p > 0.01), IL28B rs12979860 C/T variant with either CD95
rs1800682 A/G (p < 0.05) or BCL2 rs1800477 G/A variant
(p < 0.01), and CD95 rs1800682 G/G variant with IL28B
rs12979860 T/T variant (p < 0.05) or P53 rs1042522 Pro/Pro
(C/C) variant (p < 0.01) or BCL2 rs1800477 A/A variant
(p < 0.01).
Table 6 Correlation between hormonal profile and genotypes of P53 and CD95 at þ72 G/C and 670 A/G polymorphic points.
Hormonal profile (mean  SE) Gene Genotypes SVR (n Z 86) NR (n Z 74) P
Prolactin, (ng/mL) P53 72 G/G 12.91  0.69 11.29  0.71 >0.05
72 G/C 16.80  0.99 16.25  0.87 >0.05
72 C/C 9.32  0.28 12.39  0.20 <0.01
CD95 670 A/A 10.24  0.51 13.73  0.55 <0.01
670 A/G 14.02  0.79 13.12  0.57 >0.05
670 G/G 14.77  0.65 13.09  0.65 >0.05
Total Testosterone, (ng/mL) P53 72 G/G 1.74  0.21 1.83  0.36 >0.05
72 G/C 1.87  0.22 2.09  0.26 >0.05
72 C/C 2.84  0.23 1.55  0.22 <0.01
CD95 670 A/A 2.09  0.19 1.75  0.30 >0.05
670 A/G 2.26  0.22 2.01  0.28 >0.05
670 G/G 2.12  0.25 1.80  0.26 >0.05
GH, (ng/ml) P53 72 G/G 0.98  0.02 0.41  0.13 <0.01
72 G/C 0.75  0.10 0.66  0.36 >0.05
72 C/C 0.82  0.12 0.83  0.16 >0.05
CD95 670 A/A 0.84  0.06 0.56  0.12 <0.05
670 A/G 0.85  0.08 0.57  0.33 >0.05
670 G/G 0.86  0.11 0.76  0.20 >0.05
S.E.: standard error.
n: size of samples.
<0.01: represents high significant difference (P < 0.01).
<0.05: represents significant difference (P < 0.05).
>0.05: represents no significant difference (P > 0.05).
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The significance of P53 rs1042522 Arg/Pro, CD95 rs1800682
A/G, and P53 rs1042522 Arg/Pro plus CD95 rs1800682 A/G
polymorphisms as prognostic biomarkers for the HCV
treatment response (responders, n Z 86; non-responders,
n Z 74) was assessed using a receiver operating charac-
teristic (ROC) curve. The P53 rs1042522 Arg/Pro, CD95
rs1800682 A/G, and the P53 rs1042522 Arg/Pro plus CD95
rs1800682 A/G genetic polymorphisms could be used to
distinguish between the SVR and NR patients with area
under the curve (AUC) of 0.702, 0.707, and 0.710 respec-
tively (Odds ratio: 9.49, 4.61, and 5.60; 95% CI:
0.594e0.811, 0.582e0.832, and 0.630e0.790, respec-
tively), sensitivity of 90.5%, 78%, and 86% as well as speci-
ficity of 50%, 36%, and 44% respectively (p Z 0.001, 0.004,
and 0.000, respectively) as illustrated in Fig. 4.
Sensitivity and specificity of P53, CD95, IL28B, IP-
10, and IRRDR
A comparison between IL28B rs12979860, interferon
gamma-induced protein-10 (IP-10 < 150 pg/mL), IL28B
rs12979860 plus IP-10 < 150 pg/mL,40 IFN-RBV resistance-
determining region (IRRDR/NS5A of HCV-4a),41 P53
rs1042522, CD95 rs1800682, and P53 rs1042522 plus CD95
rs1800682 was illustrated in Fig. 5 in terms of sensitivity and
specificity according to sustained virological response rate
among patients infected with HCV genotype-4a. By
considering IL28B rs12979860 plus IP-10 < 150 pg/mL have
the highest specificity,30 there were high significant in-
creases when comparing this marker of response with the
remaining ones in term of specificity (p < 0.01). Whereas,by considering P53 rs1042522 has the highest sensitivity,
there were no significant increases when comparing this
response marker with IRRDR/NS5A of HCV-4a and P53
rs1042522 plus CD95 rs1800682 (p > 0.05), while there were
significant increases when comparing P53 rs1042522 with
IL28B rs12979860, IP-10 < 150 pg/mL, IL28B rs12979860 plus
IP-10 < 150 pg/mL, P53 rs1042522 (p < 0.01), and CD95
rs1800682 (p < 0.05).
Discussion
Several demographic, clinical, virological, and histological
factors were studied among responder and non-responder
patients infected with HCV genotype-4a. In addition, the
association between these factors and the response to the
antiviral therapy of pegylated-interferon and ribavirin was
investigated. This study found that there was a potential
impact of non-responsiveness to antiviral treatment on
elevating frequencies of post-treatment ALT, AST, total
bilirubin, direct bilirubin, and albumin. The statistical dif-
ferences of these hepatic tests between responders and
non-responders were supported by previous observa-
tions.42,43 Thus, the early normalization of abnormal ALT
and AST levels of HCV infection may indicate response to
antiviral treatment which agrees with numerous stud-
ies.44e48 In addition, the present study has demonstrated
that AFP was negatively associated with treatment
response in 160 HCV genotype-4a infected patients, which
supported by a previously reported study of 100 Egyptian
HCV infected patients.49
On the virological and histological side, some studies
have shown that high viral load of HCV-RNA is negatively
associated with sustained virological response to
Table 7 Logistic regression analyses of hormonal and biochemical variables in responders (SVR) and non-responders (NR).
Dependent
Variable
(Log-
transformed)
Independent
Variables
(Log-
transformed)
SVR NR
B-regression
coefficient
SE of
regression
coefficient
t P B-regression
coefficient
SE of
regression
coefficient
t P
Prolactin (A) Intercept 0.326 0.439 0.743 >0.05 0.257 0.489 0.525 >0.05
BMI 0.035 0.042 0.826 >0.05 0.047 0.049 0.966 >0.05
Testosterone (A) 0.032 0.047 0.680 >0.05 0.038 0.053 0.716 >0.05
Prolactin (B) 0.538 0.078 6.897 <0.01 0.522 0.087 5.968 <0.01
Testosterone (B) 0.176 0.051 3.473 <0.01 0.192 0.057 3.343 <0.01
ALT 0.094 0.048 1.960 >0.05 0.094 0.058 1.607 >0.05
AST 0.010 0.049 0.199 >0.05 0.006 0.058 0.100 >0.05
T. Bilirubin 0.177 0.079 2.227 <0.05 0.175 0.089 1.956 >0.05
D. Bilirubin 0.056 0.057 0.993 >0.05 0.060 0.063 0.954 >0.05
Albumin 0.291 0.184 1.582 >0.05 0.292 0.203 1.437 >0.05
Testosterone (A) Intercept 1.494 1.079 1.384 >0.05 1.469 1.144 1.284 >0.05
BMI 0.012 0.104 0.116 >0.05 0.028 0.116 0.244 >0.05
Prolactin (A) 0.195 0.287 0.680 >0.05 0.214 0.299 0.716 >0.05
Prolactin (B) 0.441 0.242 1.819 >0.05 0.470 0.253 1.860 >0.05
Testosterone (B) 0.924 0.083 11.166 <0.01 0.925 0.089 10.360 <0.01
ALT 0.032 0.122 0.264 >0.05 0.013 0.141 0.090 >0.05
AST 0.009 0.122 0.074 >0.05 0.027 0.137 0.200 >0.05
T. Bilirubin 0.212 0.202 1.053 >0.05 0.201 0.216 0.929 >0.05
D. Bilirubin 0.057 0.142 0.402 >0.05 0.054 0.149 0.365 >0.05
Albumin 0.633 0.458 1.383 >0.05 0.570 0.483 1.182 >0.05
Prolactin (B) Intercept 1.542 0.480 3.209 <0.01 1.589 0.530 2.999 <0.01
BMI 0.016 0.049 0.323 >0.05 0.028 0.057 0.495 >0.05
Prolactin (A) 0.728 0.106 6.897 <0.01 0.699 0.117 5.968 <0.01
Testosterone (A) 0.097 0.053 1.819 >0.05 0.112 0.060 1.860 >0.05
Testosterone (B) 0.010 0.064 0.152 >0.05 0.001 0.072 0.010 >0.05
ALT 0.024 0.057 0.421 >0.05 0.035 0.069 0.510 >0.05
AST 0.083 0.056 1.477 >0.05 0.070 0.066 1.056 >0.05
T. Bilirubin 0.132 0.094 1.400 >0.05 0.134 0.105 1.273 >0.05
D. Bilirubin 0.089 0.066 1.361 >0.05 0.094 0.072 1.305 >0.05
Albumin 0.247 0.216 1.145 >0.05 0.206 0.237 0.868 >0.05
Testosterone (B) Intercept 1.278 0.925 1.381 >0.05 1.030 0.989 1.042 >0.05
BMI 0.031 0.089 0.344 >0.05 0.063 0.100 0.632 >0.05
Prolactin (A) 0.796 0.229 3.473 <0.01 0.796 0.238 3.343 <0.01
Testosterone (A) 0.679 0.061 11.166 <0.01 0.685 0.066 10.360 <0.01
Prolactin (B) 0.032 0.212 0.152 >0.05 0.002 0.223 0.010 >0.05
ALT 0.099 0.104 0.950 >0.05 0.054 0.121 0.449 >0.05
AST 0.079 0.104 0.760 >0.05 0.014 0.118 0.119 >0.05
T. Bilirubin 0.279 0.171 1.631 >0.05 0.246 0.185 1.331 >0.05
D. Bilirubin 0.025 0.121 0.209 >0.05 0.025 0.128 0.192 >0.05
Albumin 0.570 0.392 1.454 >0.05 0.538 0.415 1.298 >0.05
A: pre-treatment.
B: post-treatment.
S.E.: standard error.
<0.01: represents high significant difference (P < 0.01).
<0.05: represents significant difference (P < 0.05).
>0.05: represents no significant difference (P > 0.05).
206 A.A. Abd-Rabou et al.treatment.50e52 This observation was confirmed by the
current finding which indicates that pre-treatment
response prediction was not associated with the HCV-RNA
viral loads. On the contrary, there were high statistically
significant differences of the low, moderate, and high viral
loads when comparing post-treated responders with non-
responders. In addition, there were high statisticallysignificant differences of pre- and post-treatment hepatic
activity and fibrotic scores when comparing responders
with non-responders. This finding agreed with a previous
observation indicates that high baseline viral load and high
fibrosis stage were associated with non-responsiveness to
antiviral treatment.53 On the other hand, previous studies
found that non-responders have non-significant higher
Figure 3 Response rates of IL28B rs12979860 versus P53 rs1042522, CD95 rs1800682, and BCL-2 rs1800477 polymorphisms
according to sustained virological response (SVR) in HCV genotype-4 patients. (A/A, A/B, B/B); represent C/C, C/T, T/T ge-
notypes of IL28B & G/G, G/C, CC genotypes of P53 & A/A, A/G, G/G genotypes of CD95 & G/G, G/A, A/A genotypes of BCL-2,
respectively. a; represents high significant difference (p < 0.01), b; represents significant difference (p < 0.05), and c; repre-
sents no significant difference (p > 0.05).
Genetic variations in HCV-4a response 207frequencies of viral load as well as higher grade of hepatic
activity and fibrotic stages than in responders.17,54
The present study found that Pro variant of P53
rs1042522 was high frequently found in non-responders
compared to responders, while P53 recessive genetic model
(Arg/Arg þ Arg/Pro) was frequently found in responders
compared to non-responders. Therefore, Pro variant and
recessive model of P53 rs1042522 may be used as sensitive
genetic biomarkers for non-responsiveness and respon-
siveness respectively to the antiviral dual therapy.
Numerous studies have investigated the association be-
tween P53 rs1042522 and disease severity, while there was
a lack of observations associated with treatment response.
Very recently, it was investigated that P53 rs1042522 Pro/Figure 4 ROC curve of P53 rs1042522, CD95 rs1800682, and
P53 rs 1042522 plus CD95 rs 1800682 polymorphisms.Pro and Arg/Arg genotypes may be potentially used as
sensitive genetic markers for HCV genotype-4a suscepti-
bility.38 Authors suggested that there was a frequent loss of
proline allele in HCV-positive carriers which in turn plays
critical role in hepatocarcinogenesis.10 Others investigated
that P53 genetic polymorphisms were frequently found in
patients with cirrhotic livers compared to patient with
chronic hepatitis, suggesting that P53 polymorphisms at this
stage may be a causative factor that may potentially leads
to HCC.55 On the contrary, it was investigated that there
was no association between codon þ72 genotypes and HCV
genotypes 2a and 2b infections,56 disease severity,20 or
hepatocellular carcinoma19 compared to controls. Finally,
there was a significant correlation between male homozy-
gotes for P53 72Pro with HCV type 1b infection.56
In the current study, it was investigated that A/A variant
of CD95 rs1800682 was high frequently found in responders
compared to non-responders. Therefore, A/A variant of
CD95 rs1800682 may be used as a strong polymorphic
marker for responsiveness to the interferon-based therapy.
Numerous studies have investigated the association be-
tween CD95 rs1800682 and disease severity, while there
was a lack of observations associated with the treatment
response. Recently, it was found that CD95 rs1800682 A/G
polymorphism was potentially associated with significant
fibrosis and cirrhosis in chronic HCV patients.23,38
Reference to the current study and our recently pub-
lished article,38 we can deduced that the Pro variant of P53
rs1042522 may be used as a sensitive genetic biomarker for
non-responsiveness to the antiviral dual therapy (NR:
SVRZ 85.7%: 14.3%), HCV genotype-4a susceptibility (HCV:
controls Z 17.5%: 6.25%), and severity of inflammatory-
based disease (Advanced: mild fibrosis Z 28.95%: 12.5%).
Meanwhile, the A/A variant of CD95 rs1800682 may be used
as a strong polymorphic marker for responsiveness to the
Figure 5 Comparative sensitivity and specificity of IL28B (rs12979860), IP-10<150 pg/mL, IL28B (rs12979860) plus IP-10<150 pg/
mL, IRRDR (HCV-4a), P53 rs1042522, CD95 rs1800682, and P53 rs1042522 plus CD95 rs 1800682 in order to discriminate between the
responders and non-responders among the chronic HCV genotype-4a patients.
208 A.A. Abd-Rabou et al.antiviral therapy (SVR: NR Z 77.8%: 22.2%) and HCV
clearance (Controls: HCV Z 36.25%: 22.5%; Mild: advanced
fibrosis Z 29.1%: 13.2%).
The present finding was agreed with Ksiaa’s findings who
found a higher frequency of the A/A genotype of the CD95
gene in spontaneously recovered patients from HCV than in
patients with persistent HCV infection.24 They concluded
that the A/A genotype of the CD95 gene influences the
outcome of HCV infection in patients on hemodialysis. In
addition, Aguilar-Reina group investigated that there was
an association between the CD95 rs1800682 A/G poly-
morphic spot and the grade of necrosis in chronic HCV pa-
tients.57 Conversely, others demonstrated that there was
no correlation between CD95 promoter genotypes and
fibrotic stages as well as CD95 gene polymorphism may
account for some of the histopathological variability in HCV
infection.25
Viral eradication from infected cells through apoptosis16
and inhibiting viral replication through enhancing immune
response10 are two crucial processes associated with
achieving viral clearance. It was suggested that IFN-a can
induce apoptosis through BCL2 family members. Thus, BCL2
may be used as a prognostic predictor for IFN-a sensitivity
of the disease.58 Recently, the potential role of the BCL2
rs1800477 polymorphism was examined among HCV patients
treated with PEG-IFN-a and RBV antiviral therapy.17,59 Au-
thors concluded that polymorphism in BCL2 rs1800477
polymorphism can augment the current array of predictors
of therapeutic response to PEG-IFN-a/RBV in patients
infected with HCV genotype-4. On the other hand, IFN-l3,
coded by the IL28B gene, involved in the antiviral immuneresponse and inhibited HCV replication in vitro.10 In addi-
tion, the impact of the IL28B polymorphisms on HCV
treatment was investigated in genome wide association
study11 and it has been studied in several ethnicities and
various viral genotypes.12,13,60 Moreover, IL28B rs12979860
C/C genotype,39 P53 rs1042522 G/G genotype, CD95
rs1800682 A/A genotype, BCL2 rs1800477 A/A genotype17
were associated with better treatment response rates
compared to the remaining genotypes of the same poly-
morphic points.
Intriguingly, it was found that HCV genotype-4 patients
who have normal growth hormone concentrations and BCL2
43Ala genotype can successfully achieve response to
interferon-based therapy.61 In addition, the hormonal pro-
file (prolactin, total testosterone, growth hormone) pro-
vides promising biomarkers for HCV treatment response
when associated with P53 rs1042522 and CD95 rs1800682
genetic polymorphisms; where sustained virological re-
sponders have low prolactin levels and either P53 rs1042522
C/C genotype or CD95 rs1800682 A/A genotype, high total
testosterone concentrations and P53 rs1042522 C/C geno-
type, as well as high growth hormone levels and either P53
rs1042522 G/G genotype or CD95 rs1800682 A/A genotype
compared to non-responders.
Finally, we concluded that Pro variant of P53 rs1042522
may be used as a polymorphic predictor for non-
responsiveness to antiviral therapy of HCV genotype-4a
infection, while A/A variant of CD95 rs1800682 and reces-
sive model of P53 rs1042522 may be used as genetic bio-
markers for responsiveness to antiviral therapy of HCV
genotype-4a infection among Egyptian population. In
Genetic variations in HCV-4a response 209addition, the combination between the P53 rs1042522 and
CD95 rs1800682 may be used as a powerful prognostic
predictor for the HCV genotype-4a treatment response.
Intriguingly, low prolactin, high total testosterone, and high
growth hormone levels may provide promising biomarkers
for early prediction of HCV treatment response when
associated with P53 rs1042522 C/C and CD95 rs1800682 A/A
genotypes.
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